Recent studies showed that genetic inhibition of TLS through RNA-mediated depletion of Rev1, Rev3 or MAD2L2 indeed sensitizes a variety of cancer cells to DNA-damaging chemotherapeutics and suppresses the emergence of new tumor chemoresistance both in cancer cell lines and animal models [16,17,18,19]. This evidence concerns the gene MAD2L2 and cancer.